In the closing discussion, the faculty address how they choose between the available chemoimmunotherapy regimens and where the field is heading. The segment closes with the key takeaways, including reviewing the takeaways from the TOPAZ-1 study data, the consistency of independent real-world datasets, and the survival signal reported in meta-analysis.
